Aranesp Approval Introduces Competition To $1.8 Billion U.S. Cancer Anemia Market
Bush Appoints Niederhuber Chairman of NCAB
Senate Committee Approves $27 Billion for NIH, $4.6 Billion for NCI
Senate Report Calls on NCI To Expand Research in Survivorship, CAM, GYN Cancers, And Fund Five Pancreatic SPOREs
Sharon Murphy To Head New Research Center in San Antonio
The Cancer Letter Takes Summer Publication Break.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
